IL277215B2 - Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis - Google Patents

Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis

Info

Publication number
IL277215B2
IL277215B2 IL277215A IL27721520A IL277215B2 IL 277215 B2 IL277215 B2 IL 277215B2 IL 277215 A IL277215 A IL 277215A IL 27721520 A IL27721520 A IL 27721520A IL 277215 B2 IL277215 B2 IL 277215B2
Authority
IL
Israel
Prior art keywords
antibody
weeks
dose
il36r
administered
Prior art date
Application number
IL277215A
Other languages
English (en)
Hebrew (he)
Other versions
IL277215A (en
IL277215B1 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL277215A publication Critical patent/IL277215A/en
Publication of IL277215B1 publication Critical patent/IL277215B1/en
Publication of IL277215B2 publication Critical patent/IL277215B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL277215A 2018-03-14 2019-03-08 Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis IL277215B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US201862729518P 2018-09-11 2018-09-11
PCT/US2019/021335 WO2019177888A1 (en) 2018-03-14 2019-03-08 Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Publications (3)

Publication Number Publication Date
IL277215A IL277215A (en) 2020-10-29
IL277215B1 IL277215B1 (en) 2025-06-01
IL277215B2 true IL277215B2 (en) 2025-10-01

Family

ID=65904556

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277215A IL277215B2 (en) 2018-03-14 2019-03-08 Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis

Country Status (13)

Country Link
US (2) US20190284285A1 (https=)
EP (1) EP3765513A1 (https=)
JP (2) JP7404256B2 (https=)
KR (1) KR102768040B1 (https=)
CN (1) CN112272674A (https=)
AU (1) AU2019236105B2 (https=)
BR (1) BR112020016738A2 (https=)
CA (1) CA3093692A1 (https=)
CL (1) CL2020002342A1 (https=)
IL (1) IL277215B2 (https=)
MX (1) MX2020009544A (https=)
PH (1) PH12020551444A1 (https=)
WO (1) WO2019177888A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
EP3902604A1 (en) * 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CN121324515A (zh) * 2020-09-16 2026-01-13 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
WO2022192531A2 (en) * 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236471A1 (en) * 2011-11-16 2013-09-12 Boehringer Ingelheim Gmbh Anti il-36r antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
ES2274574T3 (es) 1997-08-01 2007-05-16 Schering Corporation Proteinas de membrana celular de mamifero; reactivos relacionados.
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
EP1556403A4 (en) 2002-10-03 2006-06-28 Large Scale Biology Corp MAKING MULTIMETER PROTEINS
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
MX2009002456A (es) 2006-09-08 2009-03-20 Amgen Inc Variantes de la familia il-1.
CA2685015A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
US20100221252A1 (en) 2007-06-29 2010-09-02 Schering Corporation Mdl-1 uses
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
US9124378B2 (en) 2007-10-06 2015-09-01 The Nielsen Company (Us), Llc Gathering research data
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
HRP20181598T1 (hr) 2010-06-03 2018-11-30 Abbvie Biotechnology Ltd Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
EP4223312A1 (en) * 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
DK3194583T3 (da) 2014-07-30 2021-12-20 Zumutor Biologics Inc Ikke-fucosyleret protein og fremgangsmåder dermed
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
AU2019234478A1 (en) 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
EP3902604A1 (en) 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236471A1 (en) * 2011-11-16 2013-09-12 Boehringer Ingelheim Gmbh Anti il-36r antibodies

Also Published As

Publication number Publication date
IL277215A (en) 2020-10-29
IL277215B1 (en) 2025-06-01
CL2020002342A1 (es) 2020-12-18
CN112272674A (zh) 2021-01-26
BR112020016738A2 (pt) 2020-12-15
AU2019236105B2 (en) 2025-07-31
JP2021517566A (ja) 2021-07-26
JP2024028951A (ja) 2024-03-05
AU2019236105A1 (en) 2020-08-27
WO2019177888A1 (en) 2019-09-19
CA3093692A1 (en) 2019-09-19
PH12020551444A1 (en) 2021-08-23
JP7404256B2 (ja) 2023-12-25
KR20200131871A (ko) 2020-11-24
US12503512B2 (en) 2025-12-23
US20190284285A1 (en) 2019-09-19
MX2020009544A (es) 2020-10-05
EP3765513A1 (en) 2021-01-20
US20210087285A1 (en) 2021-03-25
JP7673168B2 (ja) 2025-05-08
KR102768040B1 (ko) 2025-02-17

Similar Documents

Publication Publication Date Title
IL277215B2 (en) Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis
JP2020002171A5 (https=)
RU2019106804A (ru) Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4
JP2018508483A5 (https=)
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
AR069501A1 (es) Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
RU2020115713A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
JP2021526534A5 (https=)
JP2019531259A5 (https=)
PE20221585A1 (es) Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
PE20220487A1 (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos
JPWO2019177888A5 (https=)
IL240695B1 (en) NME inhibitors and methods of using NME inhibitors
JP2018529661A5 (https=)
MX2024014979A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer
ZA202406651B (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib
IL314896A (en) Methods of use of anti-trem2 antibodies
RU2016128223A (ru) Лечение вируса гриппа а h7n9
MX2025003298A (es) Anticuerpo anti-il-1r3 humanizado y metodos de uso
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
RU2017112967A (ru) Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич
JP2026062640A5 (https=)
JP2009538916A5 (https=)
RU2020117362A (ru) Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)